Metabolic syndrome as a risk factor for oncogenesis

Close metadata

OBJECTIVE

To study the probability of cancer development in patients with MS.

MATERIAL AND METHODS

An observational retrospective study including 994 patients (289 males and 705 females) was carried out at the outpatient center of Moscow (Diagnostic Center No. 5 of the Moscow Healthcare Department). The mean age of study patients was 62.48±13.49 years (20 to 87 years). The incidence of cancer and oncogenesis factors in patients with MS over 10 years and the association between its components (abdominal obesity, arterial hypertension, hyperglycemia, and hypertriglyceridemia) were analyzed. Odds ratios of carcinogenesis and 95% confidence intervals were estimated using the cross tables method.

RESULTS

Cancer onset was observed in every fifth patient with an MS duration of 13.5±2.41 years. Abdominal obesity was associated with an increased risk of various cancers. The most significant risk was associated with grade I obesity, metabolic disorders, and the age of patients. In addition, a retrospective analysis of data from MS patients revealed a protective effect of oral antidiabetic and hypolipidemic agents on cancer risk and mortality, although the mechanisms are not fully understood.

CONCLUSIONS

Metabolic syndrome is a risk factor for cardiovascular diseases and cancer. Cardiovascular diseases, particularly arterial hypertension, increase the risk of cancer several-fold. Hyperglycemia also increases the risk of malignant neoplasms. Dyslipidemia has no effect on cancer development; however, more detailed studies with a larger sample are needed.

Keywords:

metabolic syndrome

cancer

arterial hypertension

diabetes mellitus

dyslipidemia

Authors:

Osadchuk M.A.

I.M. Sechenov First Moscow State Medical University

SPIN RSCI: 3108-0478
Scopus AuthorID: 6701741609
ORCID: 0000-0003-0485-6802

Vasilieva I.N.

Sechenov University

Kozlov V.V.

Interdistrict Petrogradsko-Primorsky TB Dispensary No. 3

Mitrokhina O.I.

Sechenov University

Received:

08.06.2022

Accepted:

04.10.2022

List of references:

WHO (2020) Obesity and Owerweight. Accessed December 15, 2022. https://www.who.int/news-room/fact-sheets/detail/obesity-and-owerweight
Castro-Barquero S, Ruiz-León AM, Sierra-Pérez M, Estruch R, Casas R. Dietary Strategies for Metabolic Syndrome: A Comprehensive Review. Nutrients. 2020;12(10):2983. https://doi.org/10.3390/nu12102983
Chen YY, Fang WH, Wang CC, Kao TW, Chang YW, Yang HF, Wu CJ, Sun YS, Chen WL. Association of Percentage Body Fat and Metabolic Health in Offspring of Patients with Cardiovascular Diseases. Scientific Reports. 2018; 8(1):13831. https://doi.org/10.1038/s41598-018-32230-7
Litwin M, Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatric Nephrology. 2021;36:825-837. https://doi.org/10.1007/s00467-020-04579-3
Salukhov VV, Kadin DV. Obesity as a cancer risk factor. Literature review. Medicinskii sovet. 2019;4:94-102. (In Russ.). https://doi.org/10.21518/2079-701X-2019-4-94-102
Wambui G. Gathirua-Mwangi, Patrick O. Monahan, Mwangi J. Murage, Jianjun Zhang. Metabolic Syndrome and Total Cancer Mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes and Control. 2017;28(2):127-136. https://doi.org/10.1007/s10552-016-0843-1
Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, Mozaffarian D, Swinburn B, Ezzati M. The Obesity Transition: Stages of the global epidemic. Lancet. Diabetes and Endocrinology. 2019;7(3):231-240. https://doi.org/10.1016/S2213-8587(19)30026-9
Oganov RG, Mamedov MN. Nacional’nye klinicheskie rekomendacii. Vserossijskoe nauchnoe obshchestvo kardiologov. Cbornik statej. M.: OOO «Siliceya-Poligraf»; 2009. (In Russ.).
Prevention of type 2 diabetes mellitus: the role and place of metformin. Draft clinical recommendations. Endokrinologiya: novosti, mneniya, obuchenie. Preprintnoe izdanie. 2017;1:1-9. Accessed December 15, 2022. (In Russ.). https://www.endocrincentr.ru/sites/default/files/all/PRESS/07.04.17/Project_02.03.17.pdf
Hopkins BD, Goncalves MD, Cantley LC. Cantley. Obesity and Cancer Mechanisms: Cancer Metabolism. Journal of Clinical Oncology. 2016;34(35): 4277-4283. https://doi.org/10.1200/JCO.2016.67.9712
Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes and Metabolism Journal. 2021;45(3): 285-311. https://doi.org/10.4093/dmj.2020.0250
Clifton KK, Ma CX, Fontana L, Peterson LL. Intermittent fasting in the prevention and treatment of cancer. CA: A Cancer Journal for Clinicians. 2021;71(6):527-546. https://doi.org/10.3322/caac.21694
Kaprin AD, Matskeplishvili ST, Potievskaya VI, Popovkina OE, Bolotina LV, Shklyaeva AV, Poluektova MV. Cardiovascular diseases in cancer patients. Onkologiya. Zhurnal im. P.A. Gercena. 2019;8(2):139-147. (In Russ.). https://doi.org/10.17116/onkolog20198021139
Aparecida Silveira E, Vaseghi G, de Carvalho Santos AS, Kliemann N, Masoudkabir F, Noll M, Mohammadifard N, Sarrafzadegan N, de Oliveira C. Visceral Obesity and Its Shared Role in Cancer and Cardiovascular Disease: A Scoping Review of the Pathophysiology and Pharmacological Treatments. International Journal of Molecular Sciences. 2020;21(23):9042. https://doi.org/10.3390/ijms21239042
de Boer RA, Aboumsallem JP, Bracun V, Leedy D, Cheng R, Patel S, Rayan D, Zaharova S, Rymer J, Kwan JM, Levenson J, Ronco C, Thavendiranathan P, Brown SA. A new classification of cardio-oncology syndromes. Cardio-Oncology. 2021;7(1):24. https://doi.org/10.1186/s40959-021-00110-1
Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA. Heart failure stimulates tumor growth by circulating factors. Blood Circulation. 2018; 138(7):678-691. https://doi.org/10.1161/CIRCULATIONAHA.117.030816
Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, He J. Hypertension and breast cancer risk: a systematic review and meta-analysis. Scientific Reports. 2017; 7(1):44877. https://doi.org/10.1038/srep44877
van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, Mathijssen RHJ, Danser AHJ, Lang NN. Lang. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circulation Research. 2021;128(7):1040-1061. https://doi.org/10.1161/CIRCRESAHA.121.318051
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444. https://doi.org/10.1038/nature07205
Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Current Opinion in Pharmacology. 2016;29:77-89. https://doi.org/10.1016/j.coph.2016.07.005
Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Dannenberg, and Clifford A. Hudis. Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammtion. Journal of Clinical Oncology. 2016;34(35):4270-4276. https://doi.org/10.1200/JCO.2016.67.4283
Glenny EM, Coleman MF, Giles ED, Wellberg EA, Hursting SD. Designing Relevant Preclinical Rodent Models for Studying Links Between Nutrition, Obesity, Metabolism, and Cancer. Annual Review of Nutrition. 2021; 41:253-282. https://doi.org/10.1146/annurev-nutr-120420-032437
Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, Burgess S. Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank. eLife. 2020;9:e57191. https://doi.org/10.7554/eLife.57191
Davenport L. Statins and Lower Cancer Mortality; Risk Cut by Up to a Half. Medscape. June 10, 2015. https://www.medscape.com/viewarticle/846189
Fernandez CJ, George AS, Subrahmanyan NA, Pappachan JM. Epidemiological link between obesity, type 2 diabetes mellitus and cancer. World Journal of Methodology. 2021;11(3):23-45. https://doi.org/10.5662/wjm.v11.i3.23
Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocrine-Related Cancer. 2012;19(5): 27-45. https://doi.org/10.1530/ERC-11-0374
Wang M, Yang Y, Liao Z. Diabetes and cancer: Epidemiological and biological links. World Journal of Diabetes. 2020;11(6):227-238. https://doi.org/10.4239/wjd.v11.i6.227
Supabphol S, Seubwai W, Wongkham S, Saengboonmee C. High glucose: an emerging association between diabetes mellitus and cancer progression. Journal of Molecular Medicine. 2021;99(9):1175-1193. https://doi.org/10.1007/s00109-021-02096-w
Talib WH, Mahmod AI, Abuarab SF, Hasen E, Munaim AA, Haif SK, Ayyash AM, Khater S, Al-Yasari IH, Kury LTA. Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products. Molecules. 2021;26(8):2179. https://doi.org/10.3390/molecules26082179
Kim MS, Lee DY. Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus. Annals of Pediatric Endocrinology and Metabolism. 2015;20(2):69-73. https://doi.org/10.6065/apem.2015.20.2.69
Chen YC, Li H, Wang J. Mechanisms of metformin inhibiting cancer invasion and migration. American Journal of Translational Research. 2020;12(9): 4885-4901 Accessed May, 30, 2022. https://pubmed.ncbi.nlm.nih.gov/33042396/
Zlokachestvennye novoobrazovaniya v Rossii v 2020 godu (zabolevaemost’ i smertnost’). Pod red. Kaprina A.D., Starinskogo V.V., Shahzadovoj A.O. M.: MNIOI im. P.A. Gercena — filial FGBU «NMIC radiologii» Minzdrava Rossii; 2021. Accessed December 15, 2022. (In Russ.). https://glavonco.ru/cancer_register/%D0%97%D0%B0%D0%B1%D0%BE%D0%BB_2020_%D0%AD%D0%BB%D0%B5%D0%BA%D1%82%D1%80.pdf
Edward J. Evans, James DeGregori. Cells with cancer‐associated mutations overtake our tissues as we age. Aging and Cancer. 2021;2(3):82. https://doi.org/10.1002/aac2.12037

Close metadata